-

Stevanato Group to Participate in Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences.

  • Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City
  • Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London

A live webcast of each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value-added solutions to clients.

For more information, please visit: www.stevanatogroup.com.

Contacts

Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com

Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com

Stevanato Group S.p.A.

NYSE:STVN

Release Versions

Contacts

Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com

Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com

More News From Stevanato Group S.p.A.

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism...

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders’ Meeting”) held virtually on May 26, 2026, have passed. Details of the resolutions submitted to, and approved by, t...

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026. First Quarter of 2026 Highlights (comparisons to prior-year period) For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions...
Back to Newsroom